TITLE

$110 million vaccine research centre to be built in Saskatoon

AUTHOR(S)
Ehman, Amy Jo
PUB. DATE
March 2007
SOURCE
CMAJ: Canadian Medical Association Journal;3/13/2007, Vol. 176 Issue 6, p751
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the construction of an International Vaccine Center (InterVac) at the University of Saskatchewan in Canada. The research facility partly funded by the Canadian government will focus on the development and testing of vaccines for infectious diseases including SARS, avian influenza and hepatitis C. The article mentions that the facility will collaborate with pharmaceutical industries for funding and producing vaccines.
ACCESSION #
24225620

 

Related Articles

  • GSK Plans New R&D Facility for Vaccines.  // Chain Drug Review;4/27/2015, Vol. 37 Issue 7, p230 

    The article reports on the plan of pharmaceutical company GlaxoSmithKline PLC (GSK) to build a global research and development (R&D) facility for vaccines in Maryland.

  • International vaccine centre opens at U of S.  // Canadian Meat Business;Sep/Oct2011, Vol. 10 Issue 5, p27 

    The article reports that the International Vaccine Centre (InterVac), part of the University of Saskatchewan Vaccine and Infectious Disease Organization (VIDO), was opened at the Saskatoon campus on September 16, 2011.

  • Industry-Academic Research Gets $261M Boost in Ireland. Sheridan, Cormac // BioWorld International;2/27/2013, Vol. 18 Issue 9, p3 

    The article reports on the boost of new science research funding to up to U.S.$261 million in Ireland. It states that the research funding will fund seven university-industry research centers by 2019. Science Foundation Ireland (SFI) director general Mark Ferguson says that the challenge for the...

  • Surveying the best in translation. Grunseth, Matthew; Chen, Calvin; Kelly, Ryan; Cook, Sangeeta Bardhan; Megaw, George; Couture, Larry // Nature Biotechnology;May2014, Vol. 32 Issue 5, p415 

    The article focuses on how to develop a successful translational research centers. Topics include the submission of drug application-enabling studies to the U.S. Food and Drug Administration (FDA), the benefits of commercializing translational research, and the survey which provides...

  • Infant vax coverage rates high in Belgium.  // PharmacoEconomics & Outcomes News;7/28/2007, Issue 533, p7 

    The article reports about a research on infant vaccination coverage rates in Belgium. According to the researchers, infant vaccination coverage rates in Flanders, Belgium are high. The researchers carried out an EPl-based, two-stage cluster survey of 125 clusters among 107 municipalities. Data...

  • European measles outbreaks continue: Past gains lost to vaccine objections. Deresinski, Stan // Infectious Disease Alert;Jan2012, Vol. 31 Issue 4, p37 

    The importation of measles into the U.S. was discussed in these pages earlier this year. Europe was the source of a number of cases and it was pointed out that between 2005 and 2008, almost 2 of 5 imported cases were the result of exposure to the virus in that region of the world. The...

  • Stochastic multitype epidemics in a community of households: Estimation of threshold parameter R* and secure vaccination coverage. Ball, Frank G.; Britton, Tom; Lyne, Owen D. // Biometrika;Jun2004, Vol. 91 Issue 2, p345 

    This paper is concerned with estimation of the threshold parameter R* for a stochastic model for the spread of a susceptible → infective → removed epidemic among a closed, finite population that contains several types of individual and is partitioned into households. It turns out...

  • Vaccines: From Empirical Development to Rational Design. Rueckert, Christine; Guzmán, Carlos A. // PLoS Pathogens;Nov2012, Vol. 8 Issue 11, Special section p1 

    Infectious diseases are responsible for an overwhelming number of deaths worldwide and their clinical management is often hampered by the emergence of multi-drug-resistant strains. Therefore, prevention through vaccination currently represents the best course of action to combat them. However,...

  • Intranasal Vaccination Promotes Detrimental Th17-Mediated Immunity against Influenza Infection. Maroof, Asher; Yorgensen, Yvonne M.; Li, Yufeng; Evans, Jay T. // PLoS Pathogens;Jan2014, Vol. 10 Issue 1, p1 

    Influenza disease is a global health issue that causes significant morbidity and mortality through seasonal epidemics. Currently, inactivated influenza virus vaccines given intramuscularly or live attenuated influenza virus vaccines administered intranasally are the only approved options for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics